Ford, Janet
Tassorelli, Cristina
Leroux, Elizabeth
Wang, Shufang
Ayer, David
Nichols, Russell
Detke, Holland
Clinical trials referenced in this document:
Documents that mention this clinical trial
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
https://doi.org/10.1007/s11136-020-02623-1
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8
Funding for this research was provided by:
Eli Lilly and Company
Article History
Accepted: 21 August 2020
First Online: 15 September 2020
Compliance with ethical standards
:
: The following authors are employees and minor stockholders of Eli Lilly and Company or Lilly USA, LLC: JF, HD, SW, DA, and RN. CT has consulted for Allergan S.p.A., electroCore, Inc., Eli Lilly and Company, Novartis AG, and Teva Neuroscience and is also a principal investigator or collaborator for randomized controlled trials sponsored by Alder BioPharmaceuticals Inc., Eli Lilly and Company, Novartis, and Teva Pharmaceutical Industries Ltd. EL has consulted for Allergan, Aralez, Eli Lilly and Company, Novartis AG, and Teva Neuroscience.
: The study protocol was reviewed and approved by appropriate institutional review boards at each study site and was conducted according to Good Clinical Practice and the Declaration of Helsinki.
: Patients provided written informed consent before initiating study procedures.